Paclitaxel Therapeutic Drug Monitoring in Cancer Patients

Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Conditions:   Solid Tumor, Adult;   Metastatic Nonsmall Cell Lung Cancer;   Anatomic Stage IV Breast Cancer AJCC v8;   Metastatic Cervical Carcinoma;   Metastatic Ovarian Carcinoma;   Malignant Uterine Neoplasm;   Vulvar Cancer;   Invasive Breast Cancer;   Metastatic Breast Carcinoma;   Prognostic Stage IV Breast Cancer AJCC v8;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Vulvar Carcinoma;   Stage IV Cervical Cancer AJCC v8;   Stage IV Lung Cancer AJCC v8;   Stage IV Vulvar Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IVA Cervical Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Vulvar Cancer AJCC v8;   Stage IVB Cervical Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Vulvar Cancer AJCC v8;   Vulva Squamous Cell Carcinoma
Interventions:   Other: Blood draws;   Other: QLQ-CIPN20 Survey;   Other: PR-CTCAE Survey
Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 16, 2022Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine